Table 1.
Line of Therapy | Name of Drug | Trial Name | Trial Design | Standard Arm | Objective Response Rate |
Overall Survival | Progression Free Survival |
PDL1 Status |
---|---|---|---|---|---|---|---|---|
Squamous Cell Esophageal Cancer | ||||||||
Second | Pembrolizumab | Keynote 181 | open label randomized phase III | chemotherapy (paclitaxel, docetaxel, irinotecan) | 22% vs 7% (chemo) | 10.3 months vs 6.7 months (chemo) | 3.2 months vs 2.3 months (chemo) | CPS >10 |
Second | Pembrolizumab | Keynote 180 | open label single arm phase II | none | 14.3% (SCC) | 5.8 months | 2 months | CPS >10 |
Second | Nivolumab | Attraction 3 | open label randomized phase III | chemotherapy (paclitaxel or docetaxel) | 19.3% vs 21.5% (chemo) | 10.5 months vs 8.4 months (chemo) | 1.7 months vs 3.4 months (chemo) | no |
Gastroesophageal/Gastric Cancer | ||||||||
Third | Pembrolizumab | Keynote 059 | open label single arm phase II | none | 11.6% | 5.6 months | 2 months | CPS>1 |
Hepatocellular Cancer | ||||||||
Second | Pembrolizumab | Keynote 244 | open label, non-randomized Phase II | none | 17% | 12.9 months | 4.9 months | no |
Second | Nivolumab | Checkmate 040 |
open label, non-comparative, dose escalation and expansion Phase I/II | none | 15% in dose escalation phase; 20% in dose expansion phase | 83% at 6 months; 74% at 9 months | 37% at 6 months; 28% at 9 months | no |
Second | Nivolumab + Ipilimumab | Checkmate040 | open label, non-comparative, dose escalation and expansion Phase I/II | none | 33% | 23 months | 88% at 6 months; 31% at least 24 months | no |
First* | Atezolizumab + Bevacizumab | IMbrave 150 | open label randomized Phase III | sorafenib | 28% vs 12% (sorafenib) | Not est. vs 13.2 months (sorafenib) | 6.8 months vs 4.5 (sorafenib) | no |
Colorectal Cancer | ||||||||
First for dMMR/MSI-H | Pembrolizumab | Keynote 177 |
Randomized Phase III | chemotherapy (mFOLFOX6/ FOLFIRI +/- bevacizumab or cetuximab |
43.8% vs 33.1% (chemo) | Not achieved vs 10.6 months (chemo) | 16.5 months vs 8.2 months (chemo) | no |
Second for dMMR/MSI-H | Pembrolizumab | Keynote 164 |
open label single arm Phase II | none | 33% | 31.4 months | 2.3 months | no |
Second for dMMR/MSI-H | Nivolumab | Checkmate 142 | open label single arm Phase II | none | 31% | 73% at 12 months | 50.4% at 12 months | no |
Second for dMMR/MSI-H | Nivolumab + Ipilimumab | Checkmate 142 | open label single arm Phase II | none | 46% | 85% at 12 months | 71% at 12 months | no |